Seeing Is Believing

Currently out of the existing stock ratings of Jami Rubin, 43 are a BUY (56.58%), 22 are a HOLD (28.95%), 11 are a SELL (14.47%).
Analyst Jami Rubin, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 82.31% that have a potential upside of 39.38% achieved within 747 days.
Jami Rubin’s has documented 156 price targets and ratings displayed on 13 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TEVA, Teva Pharma Industries Ltd ADR at 01-Oct-2018.
Analyst best performing recommendations are on TEVA (TEVA PHARMA INDUSTRIES LTD ADR).
The best stock recommendation documented was for TEVA (TEVA PHARMA INDUSTRIES LTD ADR) at 11/6/2017. The price target of $13 was fulfilled within 11 days with a profit of $0.67 (5.43%) receiving and performance score of 4.94.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 25-Feb-2026
$260
$29.89 (12.99%)
$220
10 days ago
(25-Feb-2026)
5/6 (83.33%)
$31.56 (13.82%)
168
Hold Since 07-Jan-2026
$230
$-0.11 (-0.05%)
$240
1 months 2 days ago
(05-Feb-2026)
1/2 (50%)
$10.98 (5.01%)
8
Buy Since 24-Jan-2022
$270
$39.89 (17.34%)
$269
1 months 2 days ago
(05-Feb-2026)
16/20 (80%)
$50.98 (23.28%)
510
Hold Since 14-May-2025
$230
$-0.11 (-0.05%)
$235
1 months 8 days ago
(27-Jan-2026)
17/18 (94.44%)
$6.07 (2.71%)
279
Buy Since 16-Oct-2020
$260
$29.89 (12.99%)
$235
4 months 4 days ago
(03-Nov-2025)
15/16 (93.75%)
$49.73 (23.65%)
463
What Year was the first public recommendation made by Jami Rubin?